China's medical sector: Transaction activity and R&D progress drive value revaluation (BofA Securities)
The BofA report pointed out that China's medical and health sector is being driven by active cooperation transactions and continued research and development progress to drive the overall value revaluation.
The BofA report pointed out that China's medical and health sector is being driven by active cooperation transactions and continued research and development progress to drive the overall value revaluation. Core events include: CSPC’s siRNA collaboration with AstraZeneca, Gushengtang’s acquisition of hospital expansion, Innovent Biologics and Eli Lilly’s commercialization of CDK4/6 drugs, and the progress of Hengrui Medicine’s multiple innovative drugs. In terms of investment logic, the market is shifting from simply focusing on policy risks to focusing on the company's own R&D pipeline and commercialization capabilities. Leading companies with strong R&D and BD capabilities will receive a premium. One-sentence conclusion: The investment logic of China's medical sector is shifting from "policy game" to "fundamentals-driven". BD transactions and technology realization are the core catalysts, and the value of R&D leading allocations is highlighted. Tip: The market has a short-term reaction to individual companies' BD transactions and clinical data, but the value of the R&D pipeline and its contribution to future profits have not yet been fully and systematically priced by the market. Catalyst: Clinical trial data: clinical data readout of each company's core pipeline drugs. New deals announced: more licensing deals or mergers and acquisitions between Chinese companies and multinational pharmaceutical companies (MNCs). Medical insurance negotiation: The impact of adjustments to the national medical insurance catalog on the expansion of innovative drugs.